BVF INC/IL - Q2 2018 holdings

$1.02 Billion is the total value of BVF INC/IL's 51 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was - .

 Value Shares↓ Weighting
MRTX NewMIRATI THERAPEUTICS INC$36,729,000745,000
+100.0%
3.58%
IONS NewIONIS PHARMACEUTICALS INC$23,752,000570,000
+100.0%
2.32%
GLMD NewGALMED PHARMACEUTICALS LTD$20,963,0001,761,567
+100.0%
2.05%
FPRX NewFIVE PRIME THERAPEUTICS INC$17,862,0001,129,761
+100.0%
1.74%
MEIP NewMEI PHARMA INC$12,136,0003,080,308
+100.0%
1.18%
CDTX NewCIDARA THERAPEUTICS INC$10,039,0001,930,670
+100.0%
0.98%
SURF NewSURFACE ONCOLOGY INC$5,453,000334,333
+100.0%
0.53%
MACK NewMERRIMACK PHARMACEUTICALS INC$5,453,0001,110,588
+100.0%
0.53%
EPIX NewESSA PHARMA INC$2,090,000552,791
+100.0%
0.20%
ZYME NewZYMEWORKS INC$293,00019,804
+100.0%
0.03%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-08-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
XENON PHARMACEUTICALS INC36Q3 20234.7%
PIERIS PHARMACEUTICALS INC30Q3 20232.8%
CYTOKINETICS INC29Q4 202011.8%
INFINITY PHARMACEUTICALS INC29Q2 20234.3%
XOMA CORP DEL28Q3 20237.3%
ARQULE INC27Q4 20194.8%
CHEMOCENTRYX INC26Q3 201913.8%
CYTOMX THERAPEUTICS INC26Q3 20235.3%
CORVUS PHARMACEUTICALS INC26Q3 20232.3%
ARRAY BIOPHARMA INC25Q2 201914.5%

View BVF INC/IL's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
42024-01-29
32024-01-26
42024-01-09
42023-12-20
42023-11-17
13F-HR2023-11-14
32023-11-13
32023-11-06
42023-11-06

View BVF INC/IL's complete filings history.

Compare quarters

Export BVF INC/IL's holdings